Side-by-side · Research reference

AOD-9604vsBPC-157

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed10/47 cited

BPhase 2Reviewed9/53 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2008

~30 minHalf-life

SQ · Abdomen · Daily fasted

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

01Mechanism of Action

Parameter

AOD-9604

BPC-157

Primary target

β3-adrenergic receptor (proposed)Ng 2008

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014 Sikiric 2018

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2008

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Feedback intact?

No GH-axis or IGF-1 feedback

No known endogenous receptor; mechanism still under investigation

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2008

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Antibody development

—

02Dosage Protocols

Parameter

AOD-9604

BPC-157

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

Frequency

Once daily, fasted

Once or twice daily

Split dosing reported anecdotally for chronic injury.

Lower / starter dose

150 mcg / day

200 mcg / day

Conservative starter for new users.

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2008

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Duration

8–12 weeks per cycle

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

Bacteriostatic water, 1–2 mL

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

Half-life

~30 min plasma

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

04Side Effects & Safety

Parameter

AOD-9604

BPC-157

Injection site reaction

Mild erythema

Mild irritation (anecdotal)

GI symptoms

Rare mild nausea

None reported in PL-14736 Phase 2

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

Not reported

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

—

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

Pregnancy / OB

Avoid

Avoid — insufficient safety data

Antibody formation

—

No data (no long-term human trials)

Long-term safety

—

Unknown beyond Phase 2 trial duration

Drug interactions

—

None established

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

05Administration Protocol

Parameter

AOD-9604

BPC-157

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

5. Needle

29–31G, 4–8 mm insulin syringe.

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration